RBC Capital raised the firm's price target on Ionis Pharmaceuticals to $100 from $95 and keeps an Outperform rating on the shares. The firm cites the company's better-than-expected Q1 results along with raised 2026 revenue outlook given that the FDA recently granted priority review for Tryngolza, the analyst tells investors in a research note.
